Clinical Trials Need Diversity: 6 Proven Reasons Why

Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.

Clinical trials need broader participation because treatments tested on narrow groups of people may not work — or may work differently — for everyone else. When dementia drug trials enroll mostly white, well-educated participants living near major research centers, researchers cannot say with confidence how those drugs will perform in Black, Hispanic, rural, or lower-income patients, who often face higher dementia risk in the first place. The science is only as good as the people it studies. Consider the trials for lecanemab, one of the first drugs shown to slow early Alzheimer’s disease.

Black Americans are roughly twice as likely as white Americans to develop Alzheimer’s, yet they made up only a small fraction of the pivotal trial’s U.S. enrollment. That gap means clinicians prescribing the drug to Black patients are extrapolating from limited evidence — a problem that better recruitment could have prevented. Broader participation is not a matter of optics; it is a matter of whether medicine actually works for the people who need it.

Why Do Clinical Trials Need Broader Participation in the First Place?
How Narrow Enrollment Skews Dementia Research Results
The Trust Gap and Its Historical Roots
Practical Barriers — and What Actually Removes Them
Common Pitfalls in Diversity Efforts
What Regulators Are Now Requiring
The Road Ahead for Inclusive Dementia Research
Conclusion
Frequently Asked Questions

Why Do Clinical Trials Need Broader Participation in the First Place?

Drugs and interventions can behave differently across populations. Genetics, coexisting health conditions, diet, environment, and even differences in how diseases progress all influence whether a treatment helps, does nothing, or causes harm. The APOE4 gene variant, a major Alzheimer’s risk factor, appears to carry different levels of risk in people of African ancestry compared with European ancestry. If a trial population doesn’t reflect that diversity, its results carry hidden blind spots. There is a useful comparison from cardiology.

For decades, heart disease research enrolled mostly men, and women were later found to experience different symptoms and respond differently to some treatments — leading to years of underdiagnosis. Dementia research risks repeating that mistake. Women make up nearly two-thirds of Alzheimer’s patients, and Black and Hispanic adults face elevated risk, yet trial rosters rarely mirror those proportions. Broader participation also speeds up science. Trials that struggle to enroll enough participants get delayed or canceled outright — by some estimates, a large share of Alzheimer’s trials miss their recruitment timelines. A wider pool of willing participants means faster answers for everyone.

How Narrow Enrollment Skews Dementia Research Results

When trial participants are healthier, wealthier, and more homogeneous than real-world patients, results suffer from what researchers call limited generalizability. A drug that slows cognitive decline by 27 percent in a carefully selected trial population may deliver smaller benefits — or more side effects — in patients with diabetes, kidney disease, or vascular dementia who were excluded from the study. Exclusion criteria compound the problem. Many Alzheimer’s trials exclude people with common conditions like uncontrolled hypertension or a history of stroke.

Because those conditions are more prevalent in Black and Hispanic communities, the exclusions disproportionately filter out the very groups at highest risk. The result is a quiet feedback loop: the people most affected by dementia contribute the least data to its treatments. The warning here is important: a treatment’s published safety profile may not apply to you. ARIA — the brain swelling and microbleeding seen with anti-amyloid drugs — varies by APOE4 status, and our understanding of that risk in non-white populations remains thinner than it should be. Patients and families should ask their clinicians how well trial populations matched their own circumstances.

The Trust Gap and Its Historical Roots

Underrepresentation isn’t simply a recruitment oversight. Decades of medical mistreatment — most infamously the Tuskegee syphilis study, in which Black men were denied treatment for 40 years — created lasting, justified distrust of medical research in many communities. That history still shapes whether families volunteer for studies today.

There are signs this can change. The Alzheimer’s Association’s efforts and programs like the African American community outreach at research centers such as the Washington Heights-Inwood Columbia Aging Project in New York have shown that long-term community partnership works. The Columbia project successfully enrolled thousands of Black and Hispanic older adults by embedding research staff in the community, hiring bilingual coordinators, and returning value to participants — free memory screenings, health education, and ongoing contact rather than one-off blood draws. Trust is built slowly and locally, not through advertising campaigns.

Practical Barriers — and What Actually Removes Them

For many families, the obstacles are logistical rather than attitudinal. Trials often require dozens of visits to academic medical centers, frequently during work hours. A caregiver holding down a job while caring for a parent with dementia may simply be unable to commit. Transportation, lost wages, and the need for a study partner who can attend every visit all weigh heaviest on lower-income households. Solutions exist, with tradeoffs.

Decentralized trials — using home visits, telehealth assessments, and local labs — dramatically reduce participant burden but make standardized cognitive testing harder to control and can introduce measurement variability. Paying participants fairly for time and travel improves enrollment but raises ethical debates about undue inducement. On balance, most researchers now argue the bigger ethical failure is running trials that only the privileged can join. Compare two recruitment models: a traditional academic center waiting for referrals versus a community-embedded model partnering with churches, senior centers, and primary care clinics. The latter costs more upfront and takes longer to establish, but consistently yields more representative enrollment — an investment, not an expense.

Common Pitfalls in Diversity Efforts

Not all inclusion efforts succeed. A frequent failure mode is “helicopter recruitment” — arriving in a community only when a trial needs participants, then disappearing when enrollment closes. Communities recognize this pattern, and it deepens distrust rather than easing it. Another pitfall is treating diversity as a single checkbox: enrolling participants from one underrepresented group while ignoring rural residents, people with lower education levels, or non-English speakers.

There are also genuine limitations to acknowledge. Even well-designed outreach cannot fully overcome structural problems like the geographic concentration of trial sites in major cities, or the fact that earlier diagnosis — a prerequisite for many trials — is itself less common in underserved communities. Patients who are diagnosed late often no longer qualify for early-stage treatment trials. Fixing trial diversity ultimately requires fixing diagnostic disparities upstream, and that is a slower, harder project.

What Regulators Are Now Requiring

Policy is catching up. The FDA has issued guidance pushing sponsors to submit diversity action plans for late-stage trials, outlining enrollment goals by race, ethnicity, sex, and age, along with concrete strategies to meet them.

The 2022 omnibus legislation gave this push statutory teeth. As one example of impact, recent Alzheimer’s prevention trials such as the AHEAD study have set explicit enrollment targets for underrepresented groups and adapted screening (including blood-based biomarkers) to reduce the burden of qualifying — a meaningful shift from the all-comers approach of a decade ago.

The Road Ahead for Inclusive Dementia Research

The next decade will likely make participation easier and more representative. Blood tests for Alzheimer’s pathology are replacing expensive PET scans and invasive spinal taps as screening tools, which lowers the barrier for people far from academic centers.

Remote cognitive assessments, registries like the Alzheimer’s Prevention Registry, and partnerships with community health systems are widening the funnel. The open question is whether sponsors will sustain community engagement between trials — the single factor most predictive of long-term success. If they do, the evidence base for dementia treatments will finally start to look like the population living with the disease.

Conclusion

Clinical trials need broader participation because narrow enrollment produces narrow evidence. When trial populations exclude the groups at highest risk for dementia — whether by design, by geography, or by accumulated distrust — the resulting treatments carry uncertainty for exactly the patients who need them most. The fixes are known: community partnership, decentralized trial designs, fair compensation, less restrictive eligibility criteria, and regulatory pressure that holds sponsors accountable.

For families affected by dementia, the practical next step is to ask about research participation early, while more trial options remain open. Talk to your neurologist or memory clinic, explore registries such as the Alzheimer’s Prevention Registry or ClinicalTrials.gov, and ask any study team how they support participants with transportation, scheduling, and language needs. Every diverse enrollee makes the science stronger for the next family.

Frequently Asked Questions

Who can join a dementia clinical trial?

It depends on the study. Some trials need people with diagnosed Alzheimer’s or mild cognitive impairment, while prevention trials enroll healthy older adults. Most require a study partner — a family member or friend who can attend visits.

Is it safe to participate in a clinical trial?

Trials carry risks, which must be disclosed during informed consent, but they are overseen by ethics boards and safety monitoring committees. You can withdraw at any time without losing your regular medical care.

Will I get a placebo instead of real treatment?

In many trials, yes — some participants receive a placebo so researchers can measure the drug’s true effect. You will continue receiving standard care either way, and many trials offer the active drug to all participants in an extension phase.

Do trials pay for participation?

Many studies reimburse travel and time, and study-related medical tests are typically free. Compensation varies by trial, so ask the study coordinator.

How do I find trials near me?

Search ClinicalTrials.gov, the Alzheimer’s Association’s TrialMatch service, or ask your doctor or local memory clinic about open studies.

Why Clinical Trials Need Broader Participation

Table of Contents